Table 1 Dose escalation study design
From: A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Dose Level | Peginterferon alfa-2b | Ipilimumab |
|---|---|---|
−2 | 1 μg/kg/week | 3 mg/kg |
−1 | 2 μg/kg/week | 3 mg/kg |
1 | 3 μg/kg/week | 3 mg/kg |
2 | 3 μg/kg/week | 10 mg/kg |